Albuminuria reduction: The Holy Grail for kidney protection

Kidney International

Volumn 72, Issue 7, 2007, Pages 785-786

  Tuttle, K R ^a,b,c  

^a SACRED HEART MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Providence Medical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; PROTEIN;

ALBUMINURIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; HUMAN; HYPOTHESIS; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RENAL DIABETES; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URINARY EXCRETION;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; HUMANS; RAMIPRIL; TETRAZOLES;

EID: 34648825398     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002505     Document Type: Note

References (11)

1. de Zeeuw D, Remuzzi G, Parving H-H et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
2. Atkins RC, Briganti EM, Lewis JB et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.
3. Lea J, Greene T, Herbert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease. Arch Intern Med 2005; 165: 947-953.
4. de Zeeuw D, Remuzzi G, Parving H-H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
5. Eijkelkamp WBA, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
6. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005; 45: 198-202.
7. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
8. Bakris GL, Ruilope L, Locatelli F et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72: 879-885.
9. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
10. Estacio RO, Jeffers BF, Gifford N et al. Effect of blood pressure control on diabetic microvascul ar complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23: B54-B64.
11. Wright JT Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease [published erratum appears in JAMA 2006; 295: 2726]. JAMA 2002; 288: 2421-2431.